Literature DB >> 24960639

The prevalence of maternal F cells in a pregnant population and potential overestimation of foeto-maternal haemorrhage as a consequence.

Deirdre Corcoran1, Deirdre Murphy1, Jennifer C Donnelly2, Fionnuala Ni Ainle3.   

Abstract

BACKGROUND: Acid elution (AE) is used to estimate foeto-maternal haemorrhage (FMH). However AE cannot differentiate between cells containing foetal or adult haemoglobin F (F cells), potentially leading to false positive results or an overestimate of the amount of FMH. The prevalence of F cells in pregnant populations remains poorly characterised. The purpose of this study was to ascertain the incidence of HbF-containing red cells in our pregnant population using anti-HbF-fluorescein isothiocyanate flow cytometry (anti-HbF FC) and to assess whether its presence leads to a significant overestimate of FMH.
MATERIAL AND METHODS: Eighty-eight pregnant patients were assessed for the presence of F cells and foetal red cells by AE and anti-HbF FC. The "FMH equivalent", estimated by AE and anti-HbF FC, was calculated.
RESULTS: Thirty-six percent of the pregnant population had F-cell populations detectable by anti-HbF FC while AE detected F cells in 48% of the population. The mean estimated FMH equivalent determined by AE and anti-HbF FC was 0.59 mL (0-23.93 mL) and 0.41 (0 to 2.19 mL), respectively (p=0.012). In 3% of our population, AE overestimated the FMH by >3 mL due to the presence of an F-cell population of at least 16%. DISCUSSION: Thirty-six percent of a prospectively evaluated group of consecutive pregnant women were found to have F-cell populations. In some patients, these findings were clinically significant as AE overestimated the degree of FMH as a consequence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24960639      PMCID: PMC4212039          DOI: 10.2450/2014.0297-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  18 in total

Review 1.  Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias.

Authors:  D J Weatherall
Journal:  Nat Rev Genet       Date:  2001-04       Impact factor: 53.242

2.  False positive Kleihauer tests and unnecessary administration of anti-D immunoglobulin.

Authors:  R Iyer; B McElhinney; N Heasley; M Williams; K Morris
Journal:  Clin Lab Haematol       Date:  2003-12

Review 3.  Sickle-cell disease.

Authors:  Marie J Stuart; Ronald L Nagel
Journal:  Lancet       Date:  2004 Oct 9-15       Impact factor: 79.321

4.  False positive Kleihauer-Betke (acid elution) test caused by elevated maternal fetal haemoglobin F cells.

Authors:  Jennifer C Donnelly; Sharon M Cooley; Aoife Doyle; Deirdre Murphy; Deirdre Corcoran; Belinda Kumpel; Fionnuala Ní Ainle
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-10-17       Impact factor: 2.435

Review 5.  Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects.

Authors:  E S Sebring; H F Polesky
Journal:  Transfusion       Date:  1990-05       Impact factor: 3.157

6.  Quantitation of transplacental haemorrhage.

Authors:  P L Mollison
Journal:  Br Med J       Date:  1972-07-01

7.  F-cells in the adult: normal values and levels in individuals with hereditary and acquired elevations of Hb F.

Authors:  W G Wood; G Stamatoyannopoulos; G Lim; P E Nute
Journal:  Blood       Date:  1975-11       Impact factor: 22.113

8.  The estimation of fetal haemoglobin in healthy adults by radioimmunoassay.

Authors:  P C Rutland; M E Pembrey; T Davies
Journal:  Br J Haematol       Date:  1983-04       Impact factor: 6.998

9.  Pattern of maternal F-cell production during pregnancy.

Authors:  N Popat; W G Wood; D J Weatherall; A C Turnbull
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

10.  Quantitation of fetomaternal haemorrhage and F cells in unusual maternal blood samples by flow cytometry using anti-D and anti-HbF.

Authors:  B M Kumpel; A P MacDonald; D R Bishop; A F Yates; E Lee
Journal:  Transfus Med       Date:  2013-04-11       Impact factor: 2.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.